Notice: This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends TROV vs. FENC, OCGN, IPHA, INMB, PLX, GNFT, CCCC, CRGX, CDTX, and CGENShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Fennec Pharmaceuticals (FENC), Ocugen (OCGN), Innate Pharma (IPHA), INmune Bio (INMB), Protalix BioTherapeutics (PLX), Genfit (GNFT), C4 Therapeutics (CCCC), CARGO Therapeutics (CRGX), Cidara Therapeutics (CDTX), and Compugen (CGEN). These companies are all part of the "medical" sector. Cardiff Oncology vs. Fennec Pharmaceuticals Ocugen Innate Pharma INmune Bio Protalix BioTherapeutics Genfit C4 Therapeutics CARGO Therapeutics Cidara Therapeutics Compugen Fennec Pharmaceuticals (NASDAQ:FENC) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends. Is FENC or TROV more profitable? Fennec Pharmaceuticals has a net margin of -2.30% compared to Cardiff Oncology's net margin of -3,688.31%. Fennec Pharmaceuticals' return on equity of -53.38% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Fennec Pharmaceuticals-2.30% -53.38% -2.08% Cardiff Oncology -3,688.31%-202.00%-122.92% Do analysts recommend FENC or TROV? Fennec Pharmaceuticals currently has a consensus price target of $13.67, indicating a potential upside of 112.05%. Given Fennec Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Fennec Pharmaceuticals is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, FENC or TROV? Fennec Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Do insiders & institutionals have more ownership in FENC or TROV? 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 11.0% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer FENC or TROV? Cardiff Oncology received 200 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 66.67% of users gave Fennec Pharmaceuticals an outperform vote. CompanyUnderperformOutperformFennec PharmaceuticalsOutperform Votes20266.67% Underperform Votes10133.33% Cardiff OncologyOutperform Votes40273.09% Underperform Votes14826.91% Does the media prefer FENC or TROV? In the previous week, Fennec Pharmaceuticals had 23 more articles in the media than Cardiff Oncology. MarketBeat recorded 23 mentions for Fennec Pharmaceuticals and 0 mentions for Cardiff Oncology. Fennec Pharmaceuticals' average media sentiment score of 0.04 beat Cardiff Oncology's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Fennec Pharmaceuticals Neutral Cardiff Oncology Neutral Which has higher earnings & valuation, FENC or TROV? Fennec Pharmaceuticals has higher revenue and earnings than Cardiff Oncology. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFennec Pharmaceuticals$49.35M3.60-$16.05M-$0.10-64.45Cardiff Oncology$250K157.68-$16.41M-$2.80-1.28 SummaryFennec Pharmaceuticals beats Cardiff Oncology on 14 of the 19 factors compared between the two stocks. Remove Ads Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.42M$3.07B$5.68B$8.01BDividend YieldN/A1.47%4.89%4.04%P/E Ratio-1.1828.0823.8518.90Price / Sales157.68364.80381.20118.45Price / CashN/A168.6838.0534.62Price / Book3.813.416.834.18Net Income-$16.41M-$71.72M$3.19B$246.59M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$3.58-6.8%N/A-5.0%$39.42M$250,000.00-1.18N/AFENCFennec Pharmaceuticals1.516 of 5 stars$6.77-3.6%$13.67+101.9%-32.4%$186.60M$49.35M-67.69N/AAnalyst ForecastAnalyst RevisionNews CoverageOCGNOcugen0.9617 of 5 stars$0.61-7.2%$6.00+891.6%-42.0%$176.28M$4.70M-3.3680Earnings ReportAnalyst RevisionIPHAInnate Pharma2.7198 of 5 stars$2.09-1.4%$11.50+450.2%-18.2%$175.21M$24.85M0.00220Short Interest ↑INMBINmune Bio2.1237 of 5 stars$7.74-3.6%$22.80+194.6%-30.3%$171.61M$42,000.00-3.5510Positive NewsPLXProtalix BioTherapeutics1.9175 of 5 stars$2.31-0.9%$15.00+549.4%+56.4%$170.10M$45.67M-17.77200High Trading VolumeGNFTGenfit2.1063 of 5 stars$3.40-2.0%$13.00+282.4%+0.3%$169.99M$76.06M0.00120Positive NewsHigh Trading VolumeCCCCC4 Therapeutics2.3033 of 5 stars$2.40-11.4%$12.50+420.8%-80.7%$169.41M$33.67M-1.41150CRGXCARGO Therapeutics2.2538 of 5 stars$3.68-2.1%$15.00+307.6%-86.9%$169.38MN/A-0.86116CDTXCidara Therapeutics4.2647 of 5 stars$23.05-7.4%$32.20+39.7%+58.9%$162.43M$44.65M-0.9090Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpCGENCompugen1.4021 of 5 stars$1.81-5.7%$4.00+121.0%-41.7%$161.52M$59.85M90.5070 Remove Ads Related Companies and Tools Related Companies FENC Competitors OCGN Competitors IPHA Competitors INMB Competitors PLX Competitors GNFT Competitors CCCC Competitors CRGX Competitors CDTX Competitors CGEN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TROV) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump announces revenge on BidenA former CIA insider just made a stunning prediction: Trump’s revenge on Biden will end America’s energy cr...Paradigm Press | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
